These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9794366)

  • 1. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
    Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
    Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    FEMS Immunol Med Microbiol; 2002 Feb; 32(3):179-85. PubMed ID: 11934561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
    Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
    Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
    FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
    Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
    Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
    Li Y; Kandimalla ER; Yu D; Agrawal S
    Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
    Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
    J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J; Adamsson J; Harandi AM
    Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
    Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg.
    Khajuria A; Gupta A; Malik F; Singh S; Singh J; Gupta BD; Suri KA; Suden P; Srinivas VK; Ella K; Qazi GN
    Vaccine; 2007 Jun; 25(23):4586-94. PubMed ID: 17498851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity.
    Wang D; Kandimalla ER; Yu D; Tang JX; Agrawal S
    Vaccine; 2005 Apr; 23(20):2614-22. PubMed ID: 15780444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Mizokami M; Kozuka S; Taniguchi T; Matano K; Maeyama J; Mizuno K; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2001 Jan; 19(11-12):1460-6. PubMed ID: 11163669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS; Vyas SP
    Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with liposomes induces strong mucosal immune responses in mice.
    Vadolas J; Davies JK; Wright PJ; Strugnell RA
    Eur J Immunol; 1995 Apr; 25(4):969-75. PubMed ID: 7737300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
    J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.